{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-004543","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2026-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.520431+00:00","generated_at":"2026-05-16T06:04:52.491652+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aspire Biopharma raises $2M via 8% OID debentures with 790K incentive shares","bullets":["Issued $2,173,913 principal of 8% OID debentures for $2,000,000; maturity sooner of 90 days or $8M financing event.","Debentures are non-convertible, bear no interest; 790,000 shares of common stock issued as incentive shares.","Proceeds to be used for debt repayment and working capital; offering exempt under Section 4(a)(2)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-004543","json":"https://secwatch.observer/filing/0001493152-26-004543.json","markdown":"https://secwatch.observer/filing/0001493152-26-004543.md","text":"https://secwatch.observer/filing/0001493152-26-004543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226004543/0001493152-26-004543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226004543/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:04:52.491652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0903ac9f610ae498a7a3484807b379ea4cf65ed6","claim":"Aspire Biopharma Holdings, Inc. entered into Securities Purchase Agreement with certain investors (the “Purchasers”) valued at aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000 (effective 2026-01-26).","evidence_excerpt":"On January 26, 2026, Aspire Biopharma Holdings, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers certain debentures in an aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226004543/0001493152-26-004543-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors (the “Purchasers”)"},{"label":"Value","value":"aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000"},{"label":"Effective","value":"2026-01-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}